GYENNO Technologies
GYENNO Technologies is a Shenzhen-based medical technology company founded in 2013 that develops integrated diagnosis, treatment, and patient management platforms (TITAN, ZEUS, PALLADIUM, HERCULES) alongside BRAVO and SKYWALK medical devices for Parkinson's Disease and central nervous system patients globally.
- Company typePrivate
- Founded2013
- HeadquartersShenzhen, China
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What GYENNO Technologies does
GYENNO Technologies CO., LTD. is a China-based digital health and medical technology company founded in 2013 and headquartered in Shenzhen, operating with 11-50 employees under the leadership of founder and CEO Kang Ren. The company focuses exclusively on central nervous system diseases, with Parkinson's Disease as its primary use case, and describes itself as having cultivated this field for 10 years. GYENNO serves both healthcare institutions and patients globally, distributing through a Global GYENNO platform, direct enterprise sales, and Amazon marketplace.
The company's core offering is a Next-generation Comprehensive Spatiotemporal Diagnosis and Treatment System structured around four proprietary platforms: TITAN (Medical and Engineering Research Platform supporting Digital Endpoint and Digital Academic Observational Trials), ZEUS (Intelligent Specialized Medical Center for clinical operations), PALLADIUM (Intelligent Patients Management with chronic disease monitoring), and HERCULES (Industrial Digital Intelligence Suite for healthcare operations). The portfolio also includes two medical device product lines, the BRAVO Series and SKYWALK Series, targeting Parkinson's Disease management. The underlying technology emphasizes cross-disciplinary integration of Medicine, Engineering, and Science.
GYENNO generates revenue primarily through hardware sales of medical devices and associated software platforms, with pricing not publicly disclosed. The go-to-market motion combines enterprise field sales to healthcare institutions (via direct email at [email protected]) with consumer/SMB distribution through Amazon, complemented by brand presence on Facebook and YouTube. Total disclosed funding to date is approximately $21.4M across rounds from 2014-2022, with Qiming Venture Partners, Eight Roads Ventures, and F-Prime among notable institutional investors.
GYENNO Technologies firmographics
Firmographics- Name
- GYENNO Technologies
- Legal name
- GYENNO Technologies CO., LTD.
- Website
- https://gyenno.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GYENNO Technologies is a Shenzhen-based medical technology company founded in 2013 that develops integrated diagnosis, treatment, and patient management platforms (TITAN, ZEUS, PALLADIUM, HERCULES) alongside BRAVO and SKYWALK medical devices for Parkinson's Disease and central nervous system patients globally.
- Ownership category
- akta.pro rank
GYENNO Technologies industry classification
Industry- Product category
- Neurological Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computer Systems Design and Related Services (5415)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
- akta.pro primary industry
- Neurology Telemedicine Platforms (HLALAGAC)
- akta.pro secondary industry
- Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
Keywords
Where GYENNO Technologies is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
GYENNO Technologies business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Technology Solutions: Sale of medical devices and digital health solutions for Parkinson's Disease and central nervous system diseases, including BRAVO Series and SKYWALK Series products, along with associated software platforms (TITAN, ZEUS, PALLADIUM, HERCULES)
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
GYENNO Technologies product offering
Product offeringCore offering
GYENNO Technologies develops and sells medical devices and integrated digital health platforms for the diagnosis and treatment of central nervous system diseases, with a primary focus on Parkinson's Disease. The offering combines hardware product lines (BRAVO Series and SKYWALK Series) with a comprehensive spatiotemporal diagnosis and treatment system built on four interconnected platforms: TITAN (research), ZEUS (specialized medical center), PALLADIUM (patient management), and HERCULES (industrial digital intelligence).
Product overview
GYENNO Technologies offers a unified platform-plus-modules architecture for Parkinson's Disease management. The core offering is the Next-generation Comprehensive Spatiotemporal Diagnosis and Treatment System, which integrates four platform modules: TITAN (Medical and Engineering Research Platform), ZEUS (Intelligent Specialized Medical Center), PALLADIUM (Intelligent Patients Management for chronic disease), and HERCULES (Industrial Digital Intelligence Suite). The portfolio also includes two product series — BRAVO Series and SKYWALK Series — which appear to be device or therapy product lines within this systemic medical solution ecosystem.
Differentiator
Problem solved
Functional benefit
Brands
- BRAVO Series: Product line under the BRAVO Series, part of the company's medical device offerings.
- SKYWALK Series
Products and services
- BRAVO Series A product series under the GYENNO portfolio for Parkinson's Disease management, representing one of the company's medical device product lines for neurological disease treatment.
- SKYWALK Series A product series under the GYENNO portfolio for Parkinson's Disease management, representing one of the company's medical device product lines for neurological disease treatment.
- GYENNO Next-generation Comprehensive Spatiotemporal Diagnosis and Treatment System A comprehensive integrated system combining four platform modules—TITAN (Medical and Engineering Research Platform), ZEUS (Intelligent Specialized Medical Center), PALLADIUM (Intelligent Patients Management), and HERCULES (Industrial Digital Intelligence Suite)—for Parkinson's Disease diagnosis and treatment. Targets healthcare institutions, research organizations, and chronic disease management programs.
Companies that use GYENNO Technologies
Customer profileSegments1 record
Ideal customer profiles3 records
GYENNO Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
GYENNO Technologies partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
GYENNO Technologies competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key highlights6 records
Customer concentration
GYENNO Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
GYENNO Technologies leadership team
Management profileNumber of profiles
Profiles1 record
GYENNO Technologies funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GYENNO Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GYENNO Technologies
What does GYENNO Technologies do?
GYENNO Technologies develops and sells medical devices and integrated digital health platforms for the diagnosis and treatment of central nervous system diseases, with a primary focus on Parkinson's Disease. The offering combines hardware product lines (BRAVO Series and SKYWALK Series) with a comprehensive spatiotemporal diagnosis and treatment system built on four interconnected platforms: TITAN (research), ZEUS (specialized medical center), PALLADIUM (patient management), and HERCULES (industrial digital intelligence).
Is GYENNO Technologies a public or private company?
GYENNO Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was GYENNO Technologies founded?
GYENNO Technologies was founded in 2013. It employs 11 to 50 people.
Where is GYENNO Technologies based?
GYENNO Technologies is headquartered in Shenzhen, China, in the Asia region.
How does GYENNO Technologies make money?
One revenue line is on record: medical Technology Solutions.
Does GYENNO Technologies have an API?
No public API is recorded for GYENNO Technologies.
What industry is GYENNO Technologies in?
GYENNO Technologies's product category is Neurological Medical Devices. Its primary akta.pro industry code is HLALAGAC, Neurology Telemedicine Platforms, with a secondary code of HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring). Its NAICS code is 334510 and its SIC code is 3845.